Natera, Inc. (NASDAQ:NTRA) Insider Daniel Rabinowitz Sells 787 Shares

Natera, Inc. (NASDAQ:NTRA) insider Daniel Rabinowitz sold 787 shares of the stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $91.38, for a total value of $71,916.06. Following the sale, the insider now owns 205,552 shares in the company, valued at approximately $18,783,341.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Daniel Rabinowitz also recently made the following trade(s):

• On Thursday, February 29th, Daniel Rabinowitz sold 20,526 shares of Natera stock. The stock was sold at an average price of $89.01, for a total value of $1,827,019.26.
• On Tuesday, February 27th, Daniel Rabinowitz sold 35,307 shares of Natera stock. The stock was sold at an average price of $75.09, for a total value of $2,651,202.63.

Natera Price Performance

NASDAQ NTRA traded up $2.43 during trading hours on Tuesday, reaching $91.04. 1,178,233 shares of the stock traded hands, compared to its average volume of 1,470,075. The stock has a 50 day simple moving average of $86.40 and a two-hundred day simple moving average of $66.49. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $98.82. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.10 and a quick ratio of 3.96. The company has a market cap of $10.99 billion, a price-to-earnings ratio of -24.02 and a beta of 1.37.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.09. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. The business had revenue of $311.11 million for the quarter, compared to the consensus estimate of $300.38 million. On average, analysts predict that Natera, Inc. will post -2.35 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. RiverPark Advisors LLC bought a new position in shares of Natera during the fourth quarter valued at about $27,000. Principal Securities Inc. bought a new position in shares of Natera during the fourth quarter valued at about $32,000. Arcadia Investment Management Corp MI grew its stake in shares of Natera by 47.8% during the first quarter. Arcadia Investment Management Corp MI now owns 538 shares of the medical research company’s stock valued at $49,000 after buying an additional 174 shares during the last quarter. Oliver Lagore Vanvalin Investment Group grew its stake in shares of Natera by 109.3% during the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock valued at $47,000 after buying an additional 389 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Natera during the third quarter valued at about $44,000. 99.90% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Canaccord Genuity Group increased their target price on Natera from $87.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, February 29th. The Goldman Sachs Group increased their price objective on Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Monday, April 15th. Craig Hallum began coverage on Natera in a research report on Monday, April 8th. They issued a “buy” rating and a $117.00 price objective on the stock. Piper Sandler increased their price objective on Natera from $70.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th. Finally, BTIG Research increased their price objective on Natera from $75.00 to $85.00 and gave the stock a “buy” rating in a research report on Friday, December 29th. One analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $86.40.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.